Franklin Biotechnology DiscvI(acc)EUR-H1

Performance History30/04/2024
Growth of 1,000 (EUR)
Franklin Biotechnology DiscvI(acc)EUR-H1
Fund27.3-17.5-14.415.53.8
+/-Cat-----
+/-Idx-----
 
Key Stats
NAV
16/05/2024
 EUR 24.80
Day Change -0.20%
Morningstar Category™ Other Equity
ISIN LU0889565759
Fund Size (Mil)
30/04/2024
 USD 1625.86
Share Class Size (Mil)
16/05/2024
 EUR 7.77
Max Initial Charge -
Ongoing Charge
04/03/2024
  0.96%
Investment Objective: Franklin Biotechnology DiscvI(acc)EUR-H1
The Fund’s investment objective is capital appreciation.
Returns
Trailing Returns (EUR)16/05/2024
YTD7.27
3 Years Annualised-0.78
5 Years Annualised5.16
10 Years Annualised5.25
12 Month Yield 0.00
Management
Manager Name
Start Date
Evan McCulloch
01/11/2000
Wendy Lam
01/09/2018
Click here to see others
Inception Date
26/02/2013
Advertisement
Benchmarks
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USD-
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNot Specific
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  Franklin Biotechnology DiscvI(acc)EUR-H130/04/2024
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stocks98.380.0098.38
Bonds0.000.000.00
Cash1.940.901.04
Other0.580.000.58
Top 5 Regions%
United States85.90
United Kingdom4.71
Europe - ex Euro4.19
Eurozone4.15
Canada1.05
Top 5 Sectors%
Healthcare98.89
Basic Materials1.11
Top 5 HoldingsSector%
Amgen IncHealthcareHealthcare7.08
Regeneron Pharmaceuticals IncHealthcareHealthcare6.34
Vertex Pharmaceuticals IncHealthcareHealthcare5.39
Ascendis Pharma A/S ADRHealthcareHealthcare4.07
AstraZeneca PLC ADRHealthcareHealthcare3.69
Franklin Biotechnology DiscvI(acc)EUR-H1
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookie Settings        Disclosures